Shots:

• Mammoth to receive $41M up front- $650M as future payments based upon the achievement of prespecified research- development & commercial milestones across 2 programs & is eligible to receive royalties on sales of any products
• The collaboration will bolster Vertex’s cell and genetic therapies capabilities with the addition of Mammoth’s ultra-small CRISPR systems to develop in vivo genome editing therapies for patients with serious diseases
• Mammoth’s CRISPR platform consists of a proprietary toolbox of novel ultra-compact Cas enzymes including Cas14 and Casɸ. The platform is designed to facilitate advanced delivery of in vivo gene-editing for genetic diseases

 ­ | Ref: Businesswire | Image: Vertex